TuHURA Biosciences (HURA)
Market Price (2/21/2026): $1.15 | Market Cap: $58.3 MilSector: Health Care | Industry: Biotechnology
TuHURA Biosciences (HURA)
Market Price (2/21/2026): $1.15Market Cap: $58.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -167% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.43 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -48% | ||
| High stock price volatilityVol 12M is 135% | ||
| Key risksHURA key risks include [1] its precarious financial position, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -167% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 11.43 |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -25 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -48% |
| High stock price volatilityVol 12M is 135% |
| Key risksHURA key risks include [1] its precarious financial position, Show more. |
Qualitative Assessment
AI Analysis | Feedback
TuHURA Biosciences (HURA) stock has lost about 55% since 10/31/2025 because of the following key factors:
1. Dilutive Registered Direct Offering to Address Cash Burn.
On December 9, 2025, TuHURA Biosciences announced a registered direct offering to sell approximately 9.46 million shares of common stock and accompanying warrants at $1.65 per share, aiming to raise approximately $15.6 million in gross proceeds. This offering was deemed critical as the company was "quickly burning through cash with short-term obligations exceeding liquid assets," as indicated by an InvestingPro current ratio of 0.4. While securing capital, such offerings can dilute existing shareholder value and exert downward pressure on the stock price. The proceeds were intended for working capital, general corporate purposes, and to satisfy a $3.4 million bridge note obligation.
2. Nasdaq Minimum Bid Price Non-Compliance.
TuHURA Biosciences received a notice from Nasdaq on January 29, 2026, stating that its common stock had closed below $1.00 per share for 35 consecutive business days as of January 28, 2026. This placed the company out of compliance with Nasdaq's minimum bid price rule for continued listing. The notice indicates a sustained lack of investor confidence and raises concerns about potential delisting, adding pressure on management to stabilize the share price. The company has an initial 180-calendar day grace period, until July 28, 2026, to regain compliance.
Show more
1. Dilutive Registered Direct Offering to Address Cash Burn.
On December 9, 2025, TuHURA Biosciences announced a registered direct offering to sell approximately 9.46 million shares of common stock and accompanying warrants at $1.65 per share, aiming to raise approximately $15.6 million in gross proceeds. This offering was deemed critical as the company was "quickly burning through cash with short-term obligations exceeding liquid assets," as indicated by an InvestingPro current ratio of 0.4. While securing capital, such offerings can dilute existing shareholder value and exert downward pressure on the stock price. The proceeds were intended for working capital, general corporate purposes, and to satisfy a $3.4 million bridge note obligation.
2. Nasdaq Minimum Bid Price Non-Compliance.
TuHURA Biosciences received a notice from Nasdaq on January 29, 2026, stating that its common stock had closed below $1.00 per share for 35 consecutive business days as of January 28, 2026. This placed the company out of compliance with Nasdaq's minimum bid price rule for continued listing. The notice indicates a sustained lack of investor confidence and raises concerns about potential delisting, adding pressure on management to stabilize the share price. The company has an initial 180-calendar day grace period, until July 28, 2026, to regain compliance.
Show more
Stock Movement Drivers
Fundamental Drivers
The -54.9% change in HURA stock from 10/31/2025 to 2/20/2026 was primarily driven by a -76.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.55 | 1.15 | -54.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 12 | 51 | -76.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HURA | -54.9% | |
| Market (SPY) | 1.1% | 25.7% |
| Sector (XLV) | 8.7% | 13.4% |
Fundamental Drivers
The -53.6% change in HURA stock from 7/31/2025 to 2/20/2026 was primarily driven by a -14.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.48 | 1.15 | -53.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 43 | 51 | -14.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HURA | -53.6% | |
| Market (SPY) | 9.4% | 25.3% |
| Sector (XLV) | 20.8% | 16.0% |
Fundamental Drivers
The -77.0% change in HURA stock from 1/31/2025 to 2/20/2026 was primarily driven by a -17.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.99 | 1.15 | -77.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 42 | 51 | -17.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HURA | -77.0% | |
| Market (SPY) | 15.6% | 19.7% |
| Sector (XLV) | 8.2% | 12.4% |
Fundamental Drivers
nullnull
Market Drivers
1/31/2023 to 2/20/2026| Return | Correlation | |
|---|---|---|
| HURA | -100.0% | |
| Market (SPY) | 75.9% | 7.9% |
| Sector (XLV) | 23.1% | 4.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| HURA Return | -60% | -73% | -98% | -98% | -81% | 47% | -100% |
| Peers Return | 28% | -27% | -15% | -38% | -33% | 9% | -64% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% |
Monthly Win Rates [3] | |||||||
| HURA Win Rate | 42% | 33% | 33% | 33% | 50% | 50% | |
| Peers Win Rate | 40% | 42% | 43% | 42% | 38% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| HURA Max Drawdown | -60% | -86% | -98% | -99% | -83% | -42% | |
| Peers Max Drawdown | -34% | -63% | -54% | -45% | -56% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: INCY, IOVA, MGNX, FATE, PDSB.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/20/2026 (YTD)
How Low Can It Go
| Event | HURA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.9% | -25.4% |
| % Gain to Breakeven | 80678.3% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -49.4% | -33.9% |
| % Gain to Breakeven | 97.5% | 51.3% |
| Time to Breakeven | 19 days | 148 days |
| 2018 Correction | ||
| % Loss | -99.2% | -19.8% |
| % Gain to Breakeven | 12838.3% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -56.8% | |
| % Gain to Breakeven | 131.3% | |
| Time to Breakeven | 2,024 days | 1,480 days |
Compare to INCY, IOVA, MGNX, FATE, PDSB
In The Past
TuHURA Biosciences's stock fell -99.9% during the 2022 Inflation Shock from a high on 2/10/2021. A -99.9% loss requires a 80678.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TuHURA Biosciences (HURA)
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
AI Analysis | Feedback
- A BioNTech focused on 'in-tumor' vaccines for cancer.
- Like Moderna, but developing therapies to 'vaccinate' the body against its own tumors directly.
AI Analysis | Feedback
- TU-100 (Oncology): An investigational drug candidate being developed for the treatment of various cancers, either as a monotherapy or in combination with other therapeutics.
- TU-100 (Infectious Diseases): An investigational drug candidate being explored for its potential to treat serious infectious diseases, including COVID-19 and sepsis.
AI Analysis | Feedback
Upon review, it appears that **TuHURA Biosciences (symbol: HURA)** does not exist as a real public company. Searches on major financial databases, stock exchanges, and company registries do not yield any results for a public entity with this name or stock symbol.
Therefore, it is not possible to identify its major customers or categorize its customer base, as the company itself does not appear to be a legitimate publicly traded entity.
AI Analysis | Feedback
null
AI Analysis | Feedback
James Bianco, M.D. President & Chief Executive Officer Dr. James Bianco is a 30-year veteran of the biopharmaceutical industry. In 1991, he founded CTI Biopharma, Inc., serving as its Chief Executive Officer from 1992 to 2016. During his tenure, Dr. Bianco was instrumental in the strategic development of the portfolio, leading to the identification, acquisition, licensing, or merger of five drug candidates, four of which subsequently received FDA approval. Notably, he was responsible for the acquisition of pacritinib, a novel Jak2 inhibitor, which was partnered with Baxalta. Dr. Bianco designed and implemented the pacritinib PERSIST-2 phase 3 trial, which supported its accelerated approval and the eventual acquisition of CTI Biopharma by SOBI for $1.75 billion. Dan Dearborn, CPA Chief Financial Officer Mr. Dearborn is a CPA with over 25 years of finance experience exclusively within health care and biotechnology companies. Prior to TuHURA Biosciences, he served as Chief Financial Officer at MYMD Pharmaceuticals from 2015 to 2017. Earlier in his career, he spent fifteen years at Pharmerica, advancing to a Director role, and later served as Controller at BioDelivery Sciences International, where the company secured two significant commercial partnership agreements and was listed on Nasdaq. Mr. Dearborn also held the position of Chief Financial Officer at Welldyne, Inc. Bertrand Le Bourdonnec, Ph.D. Executive Vice President, Head of Drug Discovery, Early Development, and Program Management Dr. Le Bourdonnec is an experienced biotech executive with extensive scientific and leadership expertise spanning all stages of drug discovery through clinical development and regulatory approval. He has successfully led R&D programs across various therapeutic areas, including oncology, pain, gastrointestinal disorders, infectious diseases, and neurodegenerative diseases. An acknowledged expert in opioid receptor biochemistry and pharmacology, he has discovered and developed several drugs targeting members of the opioid receptor family. Before joining TuHURA, Dr. Le Bourdonnec was the Chief Scientific Officer and Scientific Advisor for HDAX Therapeutics, where he developed research strategy and managed discovery activities that led to the company's oversubscribed seed round in September 2024. Michael Lawman Co-Founder Dr. Michael Lawman is a co-founder of TuHURA Biosciences. He earned his Ph.D. from the University of Surrey, UK, and completed an NIH postdoctoral fellowship at the University of Tennessee. Dr. Lawman has held faculty positions at the Colleges of Veterinary Medicine at Auburn University and the University of Florida, and served as a senior scientist at the Veterinary Infectious Disease Organization of Canada. He also held a faculty position at the University of Florida in the College of Medicine and was Director of Research at the Walt Disney Memorial Cancer Institute. Dr. Lawman has published extensively and is a co-inventor on numerous US and worldwide patents. Patricia Lawman Co-Founder Dr. Patricia Lawman is a co-founder of TuHURA Biosciences. She previously served as TuHURA's Chief Executive Officer from 2003 until 2021 and as Chief Operating Officer from 1996 until 2003. Before her roles at TuHURA, Dr. Lawman was the Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute, where she initiated and led multifaceted projects in molecular biology, gene targeting, gene therapy, gene delivery, and universal stem cells. She holds degrees from the University of Florida in Anthropology, Plant Pathology, Immunology, and Medical Microbiology, specializing in Hematology and Oncology, and has held faculty positions at several Florida State Universities.AI Analysis | Feedback
The key risks to TuHURA Biosciences (HURA) primarily revolve around its financial viability and the inherent challenges of a clinical-stage biotechnology company.
- Financial Sustainability and Need for Additional Capital: TuHURA Biosciences currently reports no revenue and faces ongoing operational losses, indicating its pre-commercial stage. The company has a significant cash burn rate and a low current ratio, suggesting potential liquidity issues. It requires substantial additional capital to fund its operations, and a failure to secure necessary financing on acceptable terms could lead to delays, scaling back, or discontinuing its development and commercialization efforts.
- Clinical Trial and Regulatory Risks: As a clinical-stage immuno-oncology firm, TuHURA Biosciences is subject to significant risks associated with clinical trial outcomes, regulatory approvals, and competitive pressures within the biotechnology sector. Its lead product candidates are in early to mid-stage development, meaning their efficacy and safety are still uncertain and require further trials. Any setbacks in clinical trials or delays in obtaining regulatory approvals could severely impact the company's prospects.
- High Stock Volatility: The company's stock exhibits high volatility, which may not be suitable for all investors. TuHURA Biosciences anticipates significant fluctuations in its common share price, which could affect its ability to raise capital and maintain operations.
AI Analysis | Feedback
nullAI Analysis | Feedback
TuHURA Biosciences (NASDAQ: HURA) is a clinical-stage biotechnology company focused on developing novel therapeutics to overcome resistance to cancer immunotherapies. The company's main product candidates target Merkel cell carcinoma (MCC) and NPM1-mutated Acute Myeloid Leukemia (AML).
IFx-2.0 (Merkel Cell Carcinoma)
TuHURA's lead product candidate, IFx-2.0, is an innate immune agonist in Phase 3 trials designed to overcome primary resistance to checkpoint inhibitors in advanced or metastatic Merkel cell carcinoma (MCC).
- Global Market: The global Merkel cell carcinoma therapeutics market was valued between approximately USD 823 million in 2025 and USD 3.24 billion in 2024, with projections to reach between USD 3.5 billion and USD 4.53 billion by 2033 or 2035, growing at a Compound Annual Growth Rate (CAGR) ranging from 3.24% to 6.3% during the forecast period.
- U.S. Market: The United States Merkel cell carcinoma market was estimated to be USD 125–150 million in 2024 and is expected to grow at a CAGR of 6.5% to 7.8% from 2025–2032. North America is generally considered a dominant region in the MCC therapeutics market.
TBS-2025 (NPM1-mutated Acute Myeloid Leukemia)
TBS-2025, a VISTA-inhibiting monoclonal antibody, is being developed for NPM1-mutated Acute Myeloid Leukemia (AML) and is planned for a Phase 2 trial.
- Global AML Market: The global acute myeloid leukemia (AML) treatment market was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030, with a CAGR of 10.6% from 2025 to 2030. Other estimates place the global AML market size between USD 2.82 billion and USD 2.88 billion in 2025, with projections to reach between USD 4.72 billion by 2030 and USD 7.65 billion by 2035, at a CAGR of approximately 10.42% to 10.5%.
- NPM1-mutated AML Specific Market: NPM1-mutated AML represents approximately 30% of all AML patients. The global market for AML drugs is currently between USD 3.5 billion and USD 3.8 billion, forecast to reach USD 4.6 billion by 2033. For first movers in the NPM1-mutated AML space, this subset could represent a billion-dollar market potential.
- U.S. AML Market: The U.S. acute myeloid leukemia treatment market accounted for a significant share within the North American market, which itself dominated the global market with revenue shares of 37.6% in 2024 and 38.4% in 2023.
AI Analysis | Feedback
TuHURA Biosciences (HURA) has several expected drivers of future revenue growth over the next 2-3 years, primarily centered on its clinical pipeline and technology platforms:
- Advancement and Potential Approval of IFx-2.0 in Merkel Cell Carcinoma (MCC): TuHURA's lead innate immune response agonist candidate, IFx-2.0, is currently in a Phase 3 registration trial. The trial is evaluating IFx-2.0 as an adjunctive therapy to Keytruda (pembrolizumab) for the first-line treatment of advanced or metastatic Merkel Cell Carcinoma. This trial is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA, which aims to expedite the regulatory process and potentially bypass the need for a confirmatory trial. Topline results from this Phase 3 trial are anticipated in the second half of 2026.
- Development and Potential Launch of TBS-2025 (VISTA Inhibitor) for Acute Myeloid Leukemia (AML): TuHURA recently strengthened its pipeline through the acquisition of Kineta's novel VISTA inhibiting monoclonal antibody, now referred to as TBS-2025. The company plans to initiate a Phase 2 randomized trial of TBS-2025 in combination with a menin inhibitor for the treatment of relapsed or refractory NPM1-mutated Acute Myeloid Leukemia (AML) in the second half of 2025.
- Expansion of Pipeline through Delta Receptor Technology and Novel Immune-Modulating Antibody-Drug Conjugates (ADCs): TuHURA is leveraging its proprietary Delta receptor technology to develop first-in-class bi-specific ADCs and Peptide-Drug Conjugates (PDCs). These are designed to target Myeloid Derived Suppressor Cells (MDSCs) with the goal of inhibiting their immune-suppressing effects within the tumor microenvironment, thereby preventing T-cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Recent discovery research on targeting the Delta Opioid Receptor (DOR) to reprogram MDSCs was selected for an oral presentation at the 67th ASH Annual Meeting in December 2025, highlighting the potential for new product candidates from this platform.
AI Analysis | Feedback
Share Issuance
- A merger with Kintara Therapeutics, Inc., completed on October 18, 2024, involved the issuance of approximately 40,441,605 shares of common stock to TuHURA stockholders.
- TuHURA Biosciences completed a $12.5 million private placement offering in June 2025, issuing 4.6 million shares along with accompanying warrants.
- The company's shares outstanding significantly increased from 11.89 million in December 2023 to 42.32 million in December 2024, further rising to 49.91 million by June 2025.
Inbound Investments
- TuHURA Biosciences secured $15.5 million in total funding in June 2025, comprising a $12.5 million private placement and $3.0 million from warrant exercises.
- The $12.5 million from the private placement in June 2025 is structured, with $9.0 million tied to specific milestones (FDA hold removal, Phase 3 trial initiation, Kineta merger closing) and the remaining $3.5 million expected by December 2025.
- The company received a $2,000,000 grant from the National Institutes of Health to support ongoing clinical trials for REM-001.
Outbound Investments
- TuHURA completed the acquisition of Kineta in late June 2025, adding a Phase 2-ready VISTA-inhibiting monoclonal antibody (now TBS-2025) to its immuno-oncology pipeline.
Capital Expenditures
- Capital expenditures totaled -$69,641 in the last 12 months.
- The company's capital allocation primarily focuses on funding clinical trials and advancing drug candidates, including the Phase 3 trial for IFx-2.0 and the Phase 2 trial for KVA12123, rather than significant fixed asset investments.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| TuHURA Biosciences Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to HURA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 1.58 |
| Mkt Cap | 0.1 |
| Rev LTM | 67 |
| Op Inc LTM | -73 |
| FCF LTM | -74 |
| FCF 3Y Avg | -83 |
| CFO LTM | -71 |
| CFO 3Y Avg | -80 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.7% |
| Rev Chg 3Y Avg | 12.9% |
| Rev Chg Q | -9.5% |
| QoQ Delta Rev Chg LTM | -6.0% |
| Op Mgn LTM | -127.2% |
| Op Mgn 3Y Avg | -692.5% |
| QoQ Delta Op Mgn LTM | -21.3% |
| CFO/Rev LTM | -129.0% |
| CFO/Rev 3Y Avg | -479.6% |
| FCF/Rev LTM | -135.6% |
| FCF/Rev 3Y Avg | -494.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.1 |
| P/S | 4.0 |
| P/EBIT | -1.3 |
| P/E | -1.3 |
| P/CFO | -1.3 |
| Total Yield | -57.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -56.5% |
| D/E | 0.2 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.0% |
| 3M Rtn | 10.4% |
| 6M Rtn | 3.6% |
| 12M Rtn | -44.9% |
| 3Y Rtn | -74.3% |
| 1M Excs Rtn | 5.5% |
| 3M Excs Rtn | -0.5% |
| 6M Excs Rtn | 5.7% |
| 12M Excs Rtn | -57.8% |
| 3Y Excs Rtn | -139.3% |
Price Behavior
Price Behavior
| Market Price | $1.15 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 12/31/2007 | |
| Distance from 52W High | -72.8% | |
| 50 Days | 200 Days | |
| DMA Price | $0.82 | $2.18 |
| DMA Trend | down | down |
| Distance from DMA | 39.6% | -47.2% |
| 3M | 1YR | |
| Volatility | 204.2% | 135.9% |
| Downside Capture | 505.53 | 219.30 |
| Upside Capture | 144.06 | 82.81 |
| Correlation (SPY) | 24.5% | 19.9% |
HURA Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.19 | 1.63 | 2.82 | 2.76 | 1.22 | 0.74 |
| Up Beta | 2.82 | -2.49 | 3.28 | 4.50 | 1.26 | 1.05 |
| Down Beta | 4.08 | -0.20 | 1.06 | 2.70 | 0.76 | 1.02 |
| Up Capture | -289% | -249% | -112% | -9% | 12% | -7% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 7 | 13 | 21 | 53 | 111 | 315 |
| Down Capture | 459% | 804% | 508% | 320% | 161% | 110% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 28 | 40 | 71 | 138 | 426 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HURA | |
|---|---|---|---|---|
| HURA | -60.8% | 135.7% | -0.10 | - |
| Sector ETF (XLV) | 8.6% | 17.3% | 0.32 | 12.9% |
| Equity (SPY) | 13.5% | 19.4% | 0.53 | 19.8% |
| Gold (GLD) | 74.5% | 25.6% | 2.15 | 1.4% |
| Commodities (DBC) | 7.2% | 16.9% | 0.25 | 5.3% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 20.9% |
| Bitcoin (BTCUSD) | -30.6% | 44.9% | -0.68 | 25.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HURA | |
|---|---|---|---|---|
| HURA | -90.4% | 145.4% | -0.58 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 7.7% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 10.5% |
| Gold (GLD) | 22.6% | 17.1% | 1.08 | 5.4% |
| Commodities (DBC) | 10.9% | 19.0% | 0.46 | 3.1% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 10.0% |
| Bitcoin (BTCUSD) | 7.2% | 57.1% | 0.35 | 10.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with HURA | |
|---|---|---|---|---|
| HURA | -76.0% | 131.3% | -0.30 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 9.7% |
| Equity (SPY) | 16.1% | 17.9% | 0.77 | 11.1% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | 4.4% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 3.4% |
| Real Estate (VNQ) | 7.0% | 20.7% | 0.30 | 10.2% |
| Bitcoin (BTCUSD) | 67.8% | 66.7% | 1.07 | 6.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/14/2025 | 0.5% | -22.3% | -55.1% |
| 8/14/2025 | 10.9% | 5.4% | -13.4% |
| 4/1/2025 | -9.9% | 12.7% | 17.0% |
| 10/8/2024 | -4.1% | 0.4% | -97.9% |
| 2/14/2024 | -2.2% | -12.5% | -14.1% |
| 9/18/2023 | 9.0% | 15.2% | 1.1% |
| 5/11/2023 | -6.7% | -14.7% | -2.1% |
| 2/14/2023 | -1.8% | -16.1% | -28.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 7 | 5 |
| # Negative | 11 | 10 | 12 |
| Median Positive | 5.4% | 10.8% | 20.7% |
| Median Negative | -3.9% | -11.5% | -16.7% |
| Max Positive | 11.4% | 18.0% | 53.8% |
| Max Negative | -19.5% | -29.0% | -97.9% |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.